20 May 2025 in Circulation: Heart Failure
BACKGROUND: Hypertrophic cardiomyopathy is often linked to likely pathogenic and pathogenic variants in genes encoding myofilament proteins. The exact molecular mechanisms by which these lead to cardiac dysfunction and metabolic remodeling remain incompletely understood. Hence, here, we sought to determine whether likely pathogenic and pathogenic variants in thick ( MYL2 ) and thin ( TNNI3 or TNNT2 ) filament genes modulate the myosin super-relaxed state, a critical molecular regulator of heart energetics. METHODS: We isolated cardiac strips from the septum of 13 patients with hypertrophic cardiomyopathy with MYL2 , TNNI3 , or TNNT2 gene variants and 10 nonfailing donors. We performed 2′-(or-3′)- O -( N -methylanthraniloyl) ATP chase experiments and X-ray diffraction as well as all-atomistic molecular dynamics simulations. RESULTS: We observed that, despite preserved myofilament lattice, likely pathogenic and pathogenic variants in thick and thin filament proteins have opposite effects on cardiac myosin autoinhibition and the subsequent proportion of myosin molecules in the ATP-preserving super-relaxed state. As expected, MYL2 -associated thick filament variants depressed myosin super-relaxation. However, with TNNI3 - or TNNT2 -related thin filament variants, myosin heads adopt an energy-saving biochemical hibernating state. Ultimately, these thin filament defects blunted the in vitro response to the hypertrophic cardiomyopathy–targeted inhibitor, mavacamten. CONCLUSIONS: Our findings indicate that, in hypertrophic cardiomyopathy, cardiac myosin super-relaxed state, associated ATP consumption, and in vitro mavacamten responsiveness depend on the type of myofilament variants. Our data warrant careful analyses of variant-specific responses to myosin inhibitors in the clinic.
1 June 2026 in Circulation: Heart Failure
BACKGROUND: Heart failure with reduced ejection fraction (HFrEF) affects millions worldwide and is characterized by chronic cardiac dysfunction, impaired perfusion, altered skeletal muscle energetics, and, thus, exercise intolerance. Efficient therapeutic strategies reducing the burden of the impaired muscle metabolism in HFrEF are currently lacking. Hence, in the present study, we sought to determine whether myosin dynamics and its important role in ATP consumption can constitute a potent biochemical target to optimize skeletal muscle energy usage in HFrEF. METHODS: We used skeletal muscle tissue from 11 human patients with HFrEF and 10 controls with comparable age, sex, and body mass index. We isolated individual myofibres and incubated them ex vivo with varying concentrations of a myosin inhibitor, mavacamten. We then performed 2′-(or-3′)-O-(N-Methylanthraniloyl) adenosine 5′-triphosphate chase experiments, together with LC/MS-based proteomics profiling. RESULTS: We observed a distinct regulation of acetyl-lysine sites and higher myosin energy consumption in resting muscle fibers from patients with HFrEF than in controls. When exposed to mavacamten, we found a dose-dependent reduction in myosin ATP consumption in myofibres of patients with HFrEF, reversing the pathological over-consumption. CONCLUSIONS: Skeletal muscle myosin becomes inefficient in HFrEF. Pharmacological inhibition of myosin ATPase activity offers an inventive strategy to lower muscle energy demand and potentially address metabolic disturbances in HFrEF.